Forest Laboratories, LLC v. Accord Healthcare, Inc.
1:16-cv-00375
Overview
Parties
Defendant
Forest Laboratories, LLC Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Intas Pharmaceuticals Limited NPE (University / Research)
Represented By
2 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
The Brandywine Building, 1000 West Street, Suite 1501
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Plaintiff
Allergan USA, Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Counter Claimant
Accord Healthcare, Inc. Operating Company
Represented By
2 Attorneys ListedSmith, Katzenstein, & Jenkins LLP
The Brandywine Building, 1000 West Street, Suite 1501
Smith, Katzenstein, & Jenkins LLP
1000 West Street, Suite 1501, Wilmington, DE 19801
Counter Defendant
Adamas Pharmaceuticals, Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Forest Laboratories Holdings, Ltd. NPE (Patent Assertion Entity)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8039009
Modified release formulations of memantine oral dosage forms
|
Filed: 2005-06-16
Issued: 2011-10-18
|
Active (2.3 yrs remaining)
+1377d PTA
Expires: 2029-03-24
|
|
|
US8058291
Methods and compositions for the treatment of CNS-related conditions
|
Filed: 2006-04-06
Issued: 2011-11-15
|
Active (3.0 yrs remaining)
+1339d PTA
Expires: 2029-12-05
|
|
|
US8168209
Method and composition for administering an NMDA receptor antagonist to a subject
|
Filed: 2009-07-30
Issued: 2012-05-01
|
Expired (Term Ended)
Expires: 2026-07-18
|
|
|
US8173708
Method and composition for administering an NMDA receptor antagonist to a subject
|
Filed: 2010-04-09
Issued: 2012-05-08
|
Expired (Term Ended)
Expires: 2025-12-02
|
|
|
US8283379
Methods and compositions for the treatment of CNS-related conditions
|
Filed: 2010-04-09
Issued: 2012-10-09
|
Expired (Term Ended)
Expires: 2026-05-28
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+1377 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).